Adaptive Biotechnologies Corporation
ADPT
$7.41
-$0.53-6.68%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.46M | 46.44M | 43.19M | 41.87M | 45.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.46M | 46.44M | 43.19M | 41.87M | 45.78M |
| Cost of Revenue | -44.64M | 40.83M | 23.49M | 48.30M | -53.29M |
| Gross Profit | 92.09M | 5.61M | 19.70M | -6.42M | 99.07M |
| SG&A Expenses | 39.63M | 37.81M | 38.21M | 41.92M | 42.63M |
| Depreciation & Amortization | 428.00K | 428.00K | 424.00K | 423.00K | 429.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.30M | 79.07M | 83.30M | 90.64M | 91.42M |
| Operating Income | -33.84M | -32.63M | -40.11M | -48.76M | -45.64M |
| Income Before Tax | -33.72M | -32.10M | -46.25M | -47.53M | -69.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.72M | -32.10M | -46.25M | -47.53M | -69.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 25.00K | 26.00K | 26.00K | 26.00K | 26.00K |
| Net Income | -33.69M | -32.07M | -46.22M | -47.51M | -69.44M |
| EBIT | -33.84M | -32.63M | -40.11M | -48.76M | -45.64M |
| EBITDA | -29.39M | -28.04M | -35.11M | -43.55M | -40.25M |
| EPS Basic | -0.23 | -0.22 | -0.31 | -0.33 | -0.48 |
| Normalized Basic EPS | -0.15 | -0.14 | -0.17 | -0.21 | -0.20 |
| EPS Diluted | -0.23 | -0.22 | -0.31 | -0.33 | -0.48 |
| Normalized Diluted EPS | -0.15 | -0.14 | -0.17 | -0.21 | -0.20 |
| Average Basic Shares Outstanding | 147.68M | 147.52M | 147.41M | 145.79M | 144.90M |
| Average Diluted Shares Outstanding | 147.68M | 147.52M | 147.41M | 145.79M | 144.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
